このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Development and Validation of the CervantesPROM, a New Menopause-Specific Quality-of-Life Measure (CervantesPROM)

2026年11月9日 更新者:Silvia Pilar González Rodríguez、Asociación Española para el Estudio de la Menopausia

Official Title Development and Psychometric Validation of the CervantesPROM, a New Patient-Reported Outcome Measure (PROM) of Health-Related Quality of Life in Women During the Peri and Postmenopause

The Cervantes Scale and its short form (Cervantes-SF) have been the reference instruments for measuring menopause-related quality of life in Spain for two decades, but they do not capture several of today's most prevalent symptoms (weight and body changes, mood lability, cognitive complaints, dyspareunia), they confound the presence or intensity of a symptom with its actual impact, and they contain socioculturally outdated items.

This study develops and psychometrically validates the CervantesPROM, a new self-administered, digital patient-reported outcome measure (PROM) of health-related quality of life for women aged 35 to 75 years in the menopausal transition and postmenopause, following Classical Test Theory and COSMIN standards. For each symptom, the instrument records separately whether it is present and how much it bothers the woman in daily life, which is the dimension scored for quality of life.

The project has three phases: item generation and content validity (Phase 1, completed with an expert panel), item reduction and psychometric validation (Phases 2A and 2B), and responsiveness (Phase 3). Reference values for the Spanish population are an objective of the linked SILVA study, which has its own registration.

調査の概要

状態

まだ募集していません

条件

詳細な説明

Design: observational, prospective, multicentre study conducted in Spain. No investigational product is used and the study does not modify clinical practice. Each phase starts only after a favourable opinion of the Research Ethics Committee.

Phase 1 (completed): an initial pool of 41 items was generated from existing instruments, epidemiological data and the clinical expertise of the research group, and rated by a panel of nine menopause experts for essentiality, relevance and item-domain congruence (scale-level content validity index 0.873). The resulting version 1.0 comprises 25 symptom items in 7 domains (vasomotor; sleep and energy; musculoskeletal and body-related; emotional; cognitive; genitourinary; sexual), an individualized subscale of up to 3 symptoms, and a section on impact on areas of life.

Phase 2A (item reduction): single administration of version 1.0 to 175-250 women (7 to 10 per item; operational target 250), recruited by collaborating gynaecologists in public and private settings in several Spanish provinces. Recruitment is competitive: there is no quota per investigator; the electronic case report form centrally monitors a target composition of the whole sample by age group (35-44, 45-54, 55-64 and 65-75 years: 50, 83, 67 and 50), educational level (primary or none, secondary, higher: 100, 50 and 100), menstrual status (at least 67 still menstruating with cycle changes) and symptom intensity (at least 67 mild and 67 severe). To compensate for responses excluded by the data-quality controls of the application (minimum completion time and invariant response patterns), up to 20% over-recruitment is allowed (maximum 300 women). Women currently using menopausal hormone therapy or combined hormonal contraception are excluded in this phase only, to avoid an artificial floor effect; progestogen-only methods are eligible. All recruitment is by individual invitation from an investigator who has personally checked the selection criteria, through three routes: patients during a clinic visit, patients of the investigator's own practice by a personal digital message, and women from the general population who are not patients of the investigator (for example, women accompanying a patient, relatives or women from the investigator's social or work environment). To reduce the selection bias of a purely clinical sample, the majority of participants are intended to come from the general population; the route is recorded for every participant. There is no public dissemination in this phase and participants cannot forward their access. Participants give electronic informed consent before the first question and complete the questionnaire on their own device in 15-20 minutes. Participants who separately agree are offered an optional cognitive interview of about 30 minutes after completing the questionnaire, in the clinic or by telephone, with a demonstration version that stores no answers. Verbal probing covers all 25 items; 10-12 interviews in two rounds give at least 7 women per item. Interviews are not recorded. Items are removed by a sequential procedure: non-response above 30%, low variability, inter-item correlation above 0.90 within a domain, item-total correlation below 0.30, reliability gain above 5% if deleted, and communality below 0.20 or cross-loadings in exploratory factor analysis.

Phase 2B (psychometric validation): new, independent sample of 15 to 20 women per item of the reduced version (maximum 375-500), with or without hormonal treatment, recorded as a covariate. Participants complete the reduced CervantesPROM, the Cervantes-SF, the Menopause Rating Scale II, the PHQ-8, the GAD-7, the FSFI-6 (sexually active women only) and the EQ-5D-5L with its visual analogue scale. Test-retest substudy: about 150 postmenopausal women are invited to obtain at least 100 stable women after 7-14 days.

Phase 3 (responsiveness): about 150 women who, on their physician's indication, start treatment for menopausal symptoms; the study does not intervene in the therapeutic decision. Assessments at baseline and at 3 months (reduced CervantesPROM, MRS II, EQ-5D-5L and global visual analogue scale), with a Global Rating of Change scale as anchor for the minimal important difference. Employed women who agree record absenteeism, presenteeism and interference with non-work activities once a month for three months.

Reference values for the Spanish population are an objective of the linked SILVA study (AEEM-SILVA-2026-01), with its own protocol, consent and registration; they are not part of this study.

Data protection: the application collects no direct identifiers; data are coded (pseudonymised) and stored in the European Union. Participants may separately consent to the use of their coded data in other studies on women's health, each subject to a favourable opinion of an ethics committee.

研究の種類

観察的

入学 (推定)

950

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Silvia P González Rodríguez, MD, PhD, MSc
  • 電話番号:+34 913 502 765
  • メール:presidencia@aeem.es

研究連絡先のバックアップ

  • 名前:AEEM Secretariat
  • 電話番号:+34 913 502 765
  • メール:aeem@aeem.es

研究場所

      • Madrid、スペイン
        • Asociación Española para el Estudio de la Menopausia (AEEM), Study Coordinating Centre

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

35年~75年 (大人、高齢者)

健康ボランティアの受け入れ

はい

受講資格のある性別

女性

サンプリング方法

非確率サンプル

調査対象母集団

Women aged 35 to 75 years living in Spain and able to understand Spanish, in the menopausal transition or postmenopause. In Phases 2A to 3 they are recruited by collaborating gynaecologists in several Spanish provinces, always by individual invitation after the investigator has checked the selection criteria: patients in public and private clinical settings and, in Phase 2A, preferably women from the general population who are not patients. No premenopausal control group is recruited.

説明

Inclusion Criteria:

  • Women aged 35 to 75 years, living in Spain.
  • Late reproductive stage (regular cycles with a change in menstrual flow), perimenopause or postmenopause, including early menopause and premature ovarian insufficiency; or a stage not classifiable by menstrual criteria because of hysterectomy, endometrial ablation or hormonal contraception.
  • Able to understand and complete a self-administered questionnaire in Spanish.
  • Informed consent.
  • Phase 3 only: physician's indication to start treatment for menopausal symptoms (the study does not intervene in that decision).

Exclusion Criteria:

  • Regular menstrual cycles with no menstrual change and no climacteric symptoms.
  • Active cancer under oncological treatment (a history of treated cancer is not an exclusion criterion).
  • Active or decompensated severe disease, or hospital admission in the previous 3 months (stable chronic conditions such as hypertension, diabetes or hypothyroidism are not excluded).
  • Active severe psychiatric disorder that prevents understanding or completing the questionnaire (treatment with antidepressants or anxiolytics alone is not an exclusion criterion).
  • Phase 2A only: current menopausal hormone therapy or combined hormonal contraception (pill, ring or patch). Progestogen-only methods, including the levonorgestrel intrauterine system, are eligible.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:COHORT
  • 時間の展望:PROSPECTIVE

コホートと介入

グループ/コホート
Phase 2A: item reduction

Women aged 35-75 years in the late reproductive stage, perimenopause or postmenopause, not using menopausal hormone therapy or combined hormonal contraception, who complete version 1.0 of the CervantesPROM once (target 250, maximum 300 including over-recruitment for data-quality exclusions). Includes an optional later cognitive interview in 10-12 women.

Phase 2B: psychometric validation

New, independent sample of women aged 35-75 years, with or without hormonal treatment, who complete the reduced CervantesPROM and the reference instruments once (15-20 per item, up to 500). Includes a test-retest subsample of about 150 invited, at least 100 stable.

Phase 3: responsiveness

About 150 women aged 35-75 years who start treatment for menopausal symptoms on their physician's indication, assessed at baseline and at 3 months; employed women may also complete a monthly work diary.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Number of CervantesPROM symptom items retained after item reduction
時間枠:Single questionnaire administration at enrollment (Phase 2A).

The number of symptom items retained in the reduced CervantesPROM after applying the prespecified sequential psychometric item-reduction procedure to the 25 items of version 1.0. The outcome is reported as a single integer representing the final number of retained items (possible range: 0-25).

Single questionnaire administration at enrollment (Phase 2A).
Comparative Fit Index (CFI) of the reduced CervantesPROM
時間枠:Single questionnaire administration at enrollment (Phase 2B).

CFI obtained from confirmatory factor analysis of the prespecified factor structure. Higher values indicate better model fit.

Single questionnaire administration at enrollment (Phase 2B).
Tucker-Lewis Index (TLI) of the reduced CervantesPROM
時間枠:Single questionnaire administration at enrollment (Phase 2B).

TLI obtained from confirmatory factor analysis of the prespecified factor structure. Higher values indicate better model fit.

Single questionnaire administration at enrollment (Phase 2B).
Root Mean Square Error of Approximation (RMSEA) of the reduced CervantesPROM
時間枠:Single questionnaire administration at enrollment (Phase 2B).

RMSEA obtained from confirmatory factor analysis of the prespecified factor structure. Lower values indicate better model fit.

Single questionnaire administration at enrollment (Phase 2B).
Standardized Root Mean Square Residual (SRMR) of the reduced CervantesPROM
時間枠:Single questionnaire administration at enrollment (Phase 2B).

SRMR obtained from confirmatory factor analysis of the prespecified factor structure. Lower values indicate better model fit.

Single questionnaire administration at enrollment (Phase 2B).
Cronbach's alpha of the reduced CervantesPROM total score
時間枠:Single questionnaire administration at enrollment (Phase 2B).

Cronbach's alpha coefficient calculated to assess the internal consistency of the reduced CervantesPROM total score.

Single questionnaire administration at enrollment (Phase 2B).
McDonald's omega of the reduced CervantesPROM total score
時間枠:Single questionnaire administration at enrollment (Phase 2B).

McDonald's omega coefficient calculated to assess the internal consistency of the reduced CervantesPROM total score.

Single questionnaire administration at enrollment (Phase 2B).

二次結果の測定

結果測定
メジャーの説明
時間枠
Percentage of cognitive interview item assessments indicating comprehension difficulties
時間枠:One optional interview of about 30 minutes, within 2 weeks after completing the questionnaire (Phase 2A)

The percentage of item-level assessments rated as "some difficulty" or "not understood" during structured cognitive interviews. Each participant evaluates 2-3 CervantesPROM items. The percentage ranges from 0% to 100%, with higher values indicating more comprehension difficulties (worse comprehensibility). This is a categorical assessment, not a questionnaire scale score. Verbal probing of all 25 items in 10-12 women (two rounds; at least 7 women per item): comprehension, distinction between bother and symptom intensity, response options, recall period and instructions. Comprehension problems are recorded per item and classified independently by two researchers.

One optional interview of about 30 minutes, within 2 weeks after completing the questionnaire (Phase 2A)
Test-retest reliability and measurement error
時間枠:Baseline and 7 to 14 days (Phase 2B)

Intraclass correlation coefficient and standard error of measurement between two administrations of the CervantesPROM in stable postmenopausal participants.

Baseline and 7 to 14 days (Phase 2B)
Percentage of prespecified construct validity hypotheses confirmed
時間枠:Single questionnaire administration at enrollment (Phase 2B).

Percentage of prespecified construct validity hypotheses supported by the observed correlations between the reduced CervantesPROM and reference measures of menopausal symptoms, general health, mood and sexual function. Each hypothesis is evaluated against its prespecified direction and magnitude. The outcome ranges from 0% to 100%, with higher percentages indicating stronger evidence of construct validity. Construct validity is considered adequate when at least 75% of the hypotheses are confirmed.

Single questionnaire administration at enrollment (Phase 2B).
Standardized Response Mean (SRM) of the CervantesPROM total score
時間枠:Baseline and 3 months (Phase 3).

SRM calculated as the mean change in the CervantesPROM total score from baseline to 3 months divided by the standard deviation of individual change scores. CervantesPROM scores range from 0 to 100, with higher scores indicating greater symptom-related burden.

Baseline and 3 months (Phase 3).
Work productivity loss associated with menopausal symptoms
時間枠:Monthly for 3 months (Phase 3)

Days of absenteeism, presenteeism and interference with non-work activities recorded monthly by employed participants.

Monthly for 3 months (Phase 3)
Anchor-based minimal important difference (MID) in the CervantesPROM total score
時間枠:Baseline and 3 months (Phase 3).

Minimal important difference in the CervantesPROM total score estimated using the Global Rating of Change scale at 3 months as an external anchor. The estimate will be expressed in CervantesPROM score points on a 0-100 scale.

Baseline and 3 months (Phase 3).

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Silvia P. González Rodríguez, MD, PhD, MSc、Asociación Española para el Estudio de la Menopausia

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年12月1日

一次修了 (推定)

2027年12月1日

研究の完了 (推定)

2028年12月1日

試験登録日

最初に提出

2026年11月4日

QC基準を満たした最初の提出物

2026年11月9日

最初の投稿 (実際)

2026年11月12日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月12日

QC基準を満たした最後の更新が送信されました

2026年11月9日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • AEEM-CERVANTESPROM-2026-01

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

IPD プランの説明

Individual participant data will not be shared. Data are coded and kept by the sponsor; the anonymised dataset will be kept for verification for a maximum of five years after publication of the results and then securely deleted. Coded data of participants who separately consent may be kept up to ten years and reused only in other studies on women's health with a prior favourable opinion of an ethics committee. Results will be published in aggregate form, following the COSMIN reporting guideline.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。